Servier’s Potential First-in-Class Targeted Therapy for IDH-Mutant Gliomas Granted FDA Priority Review

The FDA has assigned a Prescription Drug User Fee Act action date of August 20, 2024, for Servier’s New Drug Application for vorasidenib.

Source link
#Serviers #Potential #FirstinClass #Targeted #Therapy #IDHMutant #Gliomas #Granted #FDA #Priority #Review